Cardiol Therapeutics (CRDL) news
Recent news
Cardiol to expand Maveric to up to 150 patients
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) has announced the continued expansion of its pivotal Phase III MAVERIC trial in the United States, with plans to increase patient enrollment to up to 150 participants. The trial, evaluating CardiolRx™ for the prevention of disease recurrence in…
AInvest Wire · Sep 23, 2026Cardiol Therapeutics Inc: Existing capital expected to fund Maveric completion, with cash runway into Q1 2028
AInvest Wire · Sep 23, 2026Cardiol hits Maveric phase III 110-patient target early
AInvest Wire · Sep 23, 2026Cardiol Therapeutics - Topline results for Maveric trial anticipated in mid-2027
Cardiol Therapeutics Inc. (CIAHF) is preparing for the release of topline results from its Maveric trial, a Phase 2 clinical study evaluating the safety and efficacy of CardiolRx, a novel formulation of cannabidiol (CBD), in patients with heart failure with preserved ejection fraction (HFpEF). The…
AInvest Wire · Sep 23, 2026Cardiol Therapeutics files US$150 million preliminary base shelf prospectus including additional disclosure following review by staff of the Ontario Securities Commission
Cardiol Therapeutics Inc. (CRDL) has filed a preliminary base shelf prospectus with the Ontario Securities Commission, seeking to raise up to US$150 million through a shelf offering. The company has included additional disclosures in response to feedback from regulatory staff, indicating commitment…
AInvest Wire · Sep 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.